L’acide gadoxétique, un « nouveau » produit de contraste hépatospécifique en IRM

Tsuboyama, 2010, Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced mr imaging–correlation with expression of sinusoidal and canalicular transporters and bile accumulation, Radiology, 255, 824, 10.1148/radiol.10091557 Schwope, 2015, Gadoxetic acid: pearls and pitfalls, Abdom Imaging, 40, 2012, 10.1007/s00261-015-0354-7 Dioguardi Burgio, 2016, Avoiding pitfalls in the interpretation of gadoxetic acid-enhanced magnetic resonance imaging, Semin Ultrasound CT MR, 37, 561, 10.1053/j.sult.2016.08.002 Carlos, 2002, Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid as an intrabiliary contrast agent: preliminary assessment, AJR Am J Roentgenol, 179, 87, 10.2214/ajr.179.1.1790087 Tamada, 2011, Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers, Eur J Radiol, 80, 311, 10.1016/j.ejrad.2011.01.020 Kim, 2009, Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid, J Magn Reson Imaging, 30, 437, 10.1002/jmri.21839 Kinner, 2012, Diffusion weighted MR imaging in patients with HCC and liver cirrhosis after administration of different gadolinium contrast agents: is it still reliable?, Eur J Radiol, 81, 625, 10.1016/j.ejrad.2011.12.042 Kim, 2013, Effect of flip angle for optimization of image quality of gadoxetate disodium-enhanced biliary imaging at 1.5T, AJR Am J Roentgenol, 200, 90, 10.2214/AJR.12.8722 Davenport, 2013, Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality, Radiology, 266, 452, 10.1148/radiol.12120826 Kim, 2017, Reducing artifacts during arterial phase of gadoxetate disodium-enhanced mr imaging: dilution method versus reduced injection rate, Radiology, 283, 429, 10.1148/radiol.2016160241 Motosugi, 2009, Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), J Magn Reson Imaging, 30, 849, 10.1002/jmri.21913 Kim, 2021, Transient severe motion artifact on arterial phase in gadoxetic acid-enhanced liver magnetic resonance imaging: a systematic review and meta-analysis, Investigative Radiology Kromrey, 2020, Reduction of respiratory motion artifacts in gadoxetate-enhanced MR with a deep learning-based filter using convolutional neural network, Eur Radiol, 30, 5923, 10.1007/s00330-020-07006-1 Kim, 2016, Enhancement patterns and pseudo-washout of hepatic haemangiomas on gadoxetate disodium-enhanced liver MRI, Eur Radiol, 26, 191, 10.1007/s00330-015-3798-9 Husarik, 2011, Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents, Acad Radiol, 18, 1549, 10.1016/j.acra.2011.08.007 Karam, 2010, Focal nodular hyperplasia: central scar enhancement pattern using Gadoxetate Disodium, J Magn Reson Imaging, 32, 341, 10.1002/jmri.22262 Cannella, 2019, Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison, Eur J Radiol, 119, 108633, 10.1016/j.ejrad.2019.08.002 European Association for the Study of the Liver, 2018, Electronic address: [email protected], European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016/j.jhep.2018.03.019 Paisant, 2020, Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs, J Hepatol, 72, 937, 10.1016/j.jhep.2019.12.011 2018 Korean Liver Cancer Association-National Cancer Center Korea, 2019, Practice guidelines for the management of hepatocellular carcinoma, Gut Liver, 13, 227 Dioguardi Burgio, 2016, MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine, Abdom Radiol (NY), 41, 1546, 10.1007/s00261-016-0726-7 Khouri Chalouhi, 2019, Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine, Eur Radiol, 29, 3090, 10.1007/s00330-018-5884-2 Vanhooymissen IJSML, 2019, Intrapatient comparison of the hepatobiliary phase of Gd-BOPTA and Gd-EOB-DTPA in the differentiation of hepatocellular adenoma from focal nodular hyperplasia, J Magn Reson Imaging, 49, 700, 10.1002/jmri.26227 Vernuccio, 2021, Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting, Insights into Imaging, 12, 8, 10.1186/s13244-020-00928-w Lee, 2009, imaging with Gd-EOB-DTPA and its clinical applications, Radiographics, 29, 1707, 10.1148/rg.296095501 Ciolina, 2018, Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents, Eur Radiol, 28, 3020, 10.1007/s00330-017-5261-6 Yoon, 2019, Quantitative assessment of liver function by using gadoxetic acid-enhanced MRI: hepatocyte uptake ratio, Radiology, 290, 125, 10.1148/radiol.2018180753 Poetter-Lang, 2020, Quantification of liver function using gadoxetic acid-enhanced MRI, Abdom Radiol (NY), 45, 3532, 10.1007/s00261-020-02779-x Bastati, 2020, Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI Predict outcomes in chronic liver disease?, Radiology, 294, 98, 10.1148/radiol.2019190734 An, 2020, Abbreviated MRI for hepatocellular carcinoma screening and surveillance, RadioGraphics, 10.1148/rg.2020200104